Dysregulation of the NF-κB signaling pathway has been shown to contribute to cancer development and progression as well as to chemo-and radiotherapy-resistance [3], and selective inhibition of the NF-κB-activating pathway genes has been reported to sensitize breast cancer cell lines to doxorubicin [2, 4-6]. The gene discussed is NFKB1; the disease is breast carcinoma.